Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELMWOOD: Elafibranor in Primary Sclerosing Cholangitis
NCT05627362Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Dec 2022
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of elafibranor in Primary Sclerosing Cholangitis (PSC), sponsored by Ipsen. Started Dec 2022; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT05627362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627362.